Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | CCR2 | P41597 | 2/20 | 0.50 |
| ▸ | RBP4 | P02753 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.49 |
| ▸ | USP5 | P45974 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581482 | 0.87 | DRD2 (0.58) | DRD2CHRM4HTR2CCCR2RBP4 | |
| SCHEMBL4813515 | 0.85 | CHRM4 (0.58) | DRD2CHRM4HTR2CCCR2RBP4 | |
| SCHEMBL5535882 | 0.82 | LIPE (0.51) | HTR2CMGLL | |
| SCHEMBL27741973 | 0.82 | HTR2C (0.50) | DRD2CHRM4HTR2CCCR2RBP4 | |
| SCHEMBL15840485 | 0.81 | DRD2 (0.54) | DRD2CHRM4HTR2CUSP5EPHX2 | |
| SCHEMBL17208434 | 0.79 | DRD2 (0.55) | DRD2CHRM4HTR2CCCR2RBP4 | |
| SCHEMBL348554 | 0.79 | HSD11B1 (0.69) | DRD2CCR2MGLL | |
| SCHEMBL1065758 | 0.78 | HTR2C (0.77) | DRD2HTR2CGRM2DRD4 | |
| SCHEMBL21959006 | 0.78 | TEAD1 (0.61) | DRD2CHRM4HTR2CRBP4 | |
| SCHEMBL5447949 | 0.78 | DRD2 (0.51) | DRD2CHRM4HTR2CCCR2RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101448844-B | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists | HOFFMANN LA ROCHE | 2012-07-25 | — | — | CN | disclosed |
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| CN-101448844-A | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists | HOFFMANN LA ROCHE (CH) | 2009-06-03 | — | — | CN | disclosed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | DRD2 1770/4885CHRM4 1145/4885HTR2C 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.